|
G |
ANPEP |
alanyl aminopeptidase, membrane |
multiple interactions decreases activity |
EXP |
Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] |
CTD |
PMID:17109655 |
|
NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,087...55,373,881
|
|
G |
ENPEP |
glutamyl aminopeptidase |
multiple interactions |
EXP |
1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame] |
CTD |
PMID:8141778 |
|
NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
|
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of FOS mRNA] |
CTD |
PMID:7564105 |
|
NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
|
|
|
G |
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of FOS mRNA] |
CTD |
PMID:7564105 |
|
NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
pyrazolanthrone affects the reaction [etoxazole affects the phosphorylation of AKT1 protein] |
CTD |
PMID:31744678 |
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of BAX mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in decreased expression of BCL2 mRNA] |
CTD |
PMID:33905761 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP3 protein] |
CTD |
PMID:33905761 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 mRNA]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [[fumonisin B1 co-treated with ochratoxin A] results in increased expression of CASP9 protein] |
CTD |
PMID:33905761 |
|
NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions decreases expression |
EXP |
pyrazolanthrone inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA] pyrazolanthrone results in decreased expression of CCL2 mRNA |
CTD |
PMID:19265715 PMID:21176401 PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
decreases secretion decreases expression |
EXP |
pyrazolanthrone results in decreased secretion of CXCL8 protein pyrazolanthrone results in decreased expression of CXCL8 mRNA |
CTD |
PMID:21176401 |
|
NCBI chr 8:69,932,646...69,935,861
Ensembl chr 8:69,932,643...69,935,861
|
|
G |
FN1 |
fibronectin 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Arecoline results in increased expression of FN1 protein] |
CTD |
PMID:26908192 |
|
NCBI chr15:117,658,158...117,737,145
Ensembl chr15:117,658,099...117,731,014
|
|
G |
IFNG |
interferon gamma |
decreases expression |
EXP |
pyrazolanthrone results in decreased expression of IFNG mRNA |
CTD |
PMID:21176401 |
|
NCBI chr 5:32,477,906...32,482,670
Ensembl chr 5:32,477,906...32,482,670
|
|
G |
IL6 |
interleukin 6 |
decreases expression |
EXP |
pyrazolanthrone results in decreased expression of IL6 mRNA |
CTD |
PMID:21176401 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
decreases secretion decreases expression |
EXP |
pyrazolanthrone results in decreased secretion of IL1B protein pyrazolanthrone results in decreased expression of IL1B mRNA |
CTD |
PMID:21176401 |
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with etoxazole] results in increased phosphorylation of MAPK1 protein; pyrazolanthrone inhibits the reaction [Ivermectin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:31400776 PMID:31744678 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with etoxazole] results in increased phosphorylation of MAPK3 protein; pyrazolanthrone inhibits the reaction [Ivermectin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:31400776 PMID:31744678 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone promotes the reaction [Ivermectin results in decreased phosphorylation of MAPK8 protein] |
CTD |
PMID:31400776 PMID:31744678 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
pyrazolanthrone promotes the reaction [Ivermectin results in decreased phosphorylation of MAPK9 protein] |
CTD |
PMID:31400776 |
|
NCBI chr 2:78,338,466...78,399,108
Ensembl chr 2:78,338,376...78,399,100
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions |
EXP |
pyrazolanthrone affects the reaction [etoxazole affects the phosphorylation of RPS6 protein] |
CTD |
PMID:31744678 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
RPS6KA1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Ivermectin results in decreased phosphorylation of RPS6KA1 protein] |
CTD |
PMID:31400776 |
|
NCBI chr 6:83,905,124...83,947,189
Ensembl chr 6:83,905,077...83,950,963
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
pyrazolanthrone affects the reaction [etoxazole affects the phosphorylation of RPS6KB1 protein] |
CTD |
PMID:31744678 |
|
NCBI chr12:36,111,584...36,159,287
Ensembl chr12:36,111,653...36,160,376
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Arecoline results in increased expression of SERPINE1 protein] |
CTD |
PMID:26908192 |
|
NCBI chr 3:8,863,738...8,871,572
Ensembl chr 3:8,863,695...8,871,547
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Arecoline results in increased expression of TGFB1 mRNA] |
CTD |
PMID:26908192 |
|
NCBI chr 6:49,332,169...49,348,642
Ensembl chr 6:49,332,173...49,349,046
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
pyrazolanthrone results in decreased expression of TNF mRNA |
CTD |
PMID:21176401 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] |
CTD |
PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATM protein] |
CTD |
PMID:38104654 |
|
NCBI chr 9:36,620,656...36,759,555
Ensembl chr 9:36,620,658...36,759,552
|
|
G |
CCNB1 |
cyclin B1 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CCNB1 protein] |
CTD |
PMID:38104654 |
|
NCBI chr16:47,338,239...47,348,385
Ensembl chr16:47,338,110...47,348,377
|
|
G |
CDC25C |
cell division cycle 25C |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDC25C protein] |
CTD |
PMID:38104654 |
|
NCBI chr 2:140,289,156...140,323,696
Ensembl chr 2:140,289,115...140,324,425
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in decreased expression of CDK1 protein] |
CTD |
PMID:38104654 |
|
NCBI chr14:64,233,945...64,255,290
Ensembl chr14:64,233,987...64,372,197
|
|
G |
CHEK2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
Caffeine inhibits the reaction [deoxynivalenol results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:38104654 |
|
NCBI chr14:45,699,833...45,967,350
Ensembl chr14:45,929,715...45,967,290
|
|
G |
RYR1 |
ryanodine receptor 1 |
increases activity multiple interactions |
EXP |
Caffeine results in increased activity of RYR1 protein; Caffeine results in increased activity of RYR1 protein mutant form Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]; Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein mutant form]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein] |
CTD |
PMID:11278295 |
|
NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458
|
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
decreases activity |
EXP |
Crizotinib results in decreased activity of NTRK1 protein |
CTD |
PMID:21812414 |
|
NCBI chr 4:93,219,509...93,237,944
Ensembl chr 4:93,219,516...93,255,981
|
|
G |
NTRK2 |
neurotrophic receptor tyrosine kinase 2 |
decreases activity |
EXP |
Crizotinib results in decreased activity of NTRK2 protein |
CTD |
PMID:21812414 |
|
NCBI chr10:30,030,050...30,429,938
Ensembl chr10:30,033,405...30,429,882
|
|
|
G |
ACO2 |
aconitase 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased activity of ACO2 protein] |
CTD |
PMID:25119790 |
|
NCBI chr 5:7,014,383...7,071,023
Ensembl chr 5:7,008,719...7,071,025
|
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression |
EXP |
daidzein results in increased expression of ESR1 mRNA |
CTD |
PMID:19617652 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
ESR2 |
estrogen receptor 2 |
increases expression |
EXP |
daidzein results in increased expression of ESR2 mRNA; daidzein results in increased expression of ESR2 protein |
CTD |
PMID:19617652 |
|
NCBI chr 1:193,823,666...193,907,330
Ensembl chr 1:193,829,560...193,906,565
|
|
G |
LHB |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
daidzein inhibits the reaction [LHB protein results in increased abundance of Progesterone] |
CTD |
PMID:19617652 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; daidzein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of AKT1 protein |
CTD |
PMID:37353039 |
|
|
|
G |
PDK1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PDK1 protein |
CTD |
PMID:37353039 |
|
NCBI chr15:78,608,394...78,650,958
Ensembl chr15:78,608,432...78,652,962
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PIK3R1 protein |
CTD |
PMID:37353039 |
|
NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,511,521...46,523,609
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions |
EXP |
deguelin results in increased expression of and results in increased phosphorylation of PTEN protein |
CTD |
PMID:37353039 |
|
NCBI chr14:99,929,590...100,021,619
|
|
|
G |
ATP4A |
ATPase H+/K+ transporting subunit alpha |
multiple interactions |
EXP |
ebselen results in decreased activity of [ATP4A protein binds to ATP4B protein] |
CTD |
PMID:7590103 |
|
NCBI chr 6:44,984,014...45,057,796
Ensembl chr 6:44,984,233...44,997,552
|
|
G |
ATP4B |
ATPase H+/K+ transporting subunit beta |
multiple interactions |
EXP |
ebselen results in decreased activity of [ATP4A protein binds to ATP4B protein] |
CTD |
PMID:7590103 |
|
NCBI chr11:78,780,013...78,785,143
Ensembl chr11:78,780,013...78,785,116
|
|
|
G |
FES |
FES proto-oncogene, tyrosine kinase |
multiple interactions decreases phosphorylation |
EXP |
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein]; Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] Gefitinib results in decreased phosphorylation of FES protein |
CTD |
PMID:19885553 |
|
NCBI chr 7:53,472,947...53,485,084
Ensembl chr 7:53,472,947...53,485,082
|
|
G |
FGF2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Gefitinib inhibits the reaction [FGF2 protein results in increased phosphorylation of FES protein] |
CTD |
PMID:19885553 |
|
NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,885...101,343,916
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Gefitinib inhibits the reaction [VEGFA protein results in increased phosphorylation of FES protein] |
CTD |
PMID:19885553 |
|
NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366
|
|
|
G |
ESR1 |
estrogen receptor 1 |
decreases expression |
EXP |
Genistein results in decreased expression of ESR1 protein |
CTD |
PMID:22443950 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Genistein inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Genistein inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
multiple interactions |
EXP |
Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Chlortetracycline]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Penicillins]; Genistein inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid] |
CTD |
PMID:31287969 |
|
NCBI chr 5:52,020,303...52,133,132
Ensembl chr 5:52,049,443...52,129,730
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Genistein inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
Glyburide inhibits the reaction [Carvedilol results in decreased expression of EDN1 protein] |
CTD |
PMID:18840580 |
|
NCBI chr 7:8,752,018...8,758,354
Ensembl chr 7:8,751,695...8,758,348
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Go 6976 inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA] |
CTD |
PMID:15089098 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
|
G |
COL4A2 |
collagen type IV alpha 2 chain |
multiple interactions decreases expression |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of COL4A2 protein] KT 5823 results in decreased expression of COL4A2 protein |
CTD |
PMID:21307347 |
|
NCBI chr11:76,996,885...77,161,617
Ensembl chr11:76,997,516...77,161,614
|
|
G |
COL4A3 |
collagen type IV alpha 3 chain |
decreases expression multiple interactions |
EXP |
KT 5823 results in decreased expression of COL4A3 mRNA KT 5823 inhibits the reaction [NOC 18 results in increased expression of COL4A3 mRNA] |
CTD |
PMID:21307347 |
|
NCBI chr15:128,611,640...128,763,331
Ensembl chr15:128,611,866...128,763,122
|
|
G |
ITGAV |
integrin subunit alpha V |
multiple interactions |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of [ITGAV protein binds to ITGB3 protein]] |
CTD |
PMID:21307347 |
|
NCBI chr15:91,604,666...91,711,843
Ensembl chr15:91,604,676...91,711,851
|
|
G |
ITGB3 |
integrin subunit beta 3 |
multiple interactions |
EXP |
KT 5823 inhibits the reaction [NOC 18 results in increased expression of [ITGAV protein binds to ITGB3 protein]] |
CTD |
PMID:21307347 |
|
NCBI chr12:16,694,466...16,752,228
Ensembl chr12:16,693,514...16,752,292
|
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
decreases activity multiple interactions |
EXP |
Lapatinib results in decreased activity of FSHB protein Lapatinib inhibits the reaction [FSHB protein results in increased abundance of Progesterone] |
CTD |
PMID:23375200 |
|
NCBI chr 2:30,395,769...30,399,282
Ensembl chr 2:30,395,018...30,399,274
|
|
G |
LHB |
luteinizing hormone subunit beta |
decreases activity multiple interactions |
EXP |
Lapatinib results in decreased activity of LHB protein Lapatinib inhibits the reaction [LHB protein results in increased abundance of Progesterone] |
CTD |
PMID:23375200 |
|
NCBI chr 6:54,263,574...54,269,286
Ensembl chr 6:54,263,576...54,271,086
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [etoxazole affects the phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16239170 PMID:31744678 |
|
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
decreases expression multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of CCL2 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA] |
CTD |
PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with etoxazole] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31744678 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
[2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with etoxazole] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31744678 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [etoxazole results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:31744678 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:16239170 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [etoxazole affects the phosphorylation of RPS6 protein] |
CTD |
PMID:31744678 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [etoxazole affects the phosphorylation of RPS6KB1 protein] |
CTD |
PMID:31744678 |
|
NCBI chr12:36,111,584...36,159,287
Ensembl chr12:36,111,653...36,160,376
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] |
CTD |
PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
IL4 |
interleukin 4 |
decreases response to substance |
EXP |
IL4 protein results in decreased susceptibility to Melitten |
CTD |
PMID:20017192 |
|
NCBI chr 2:134,986,817...134,994,365
Ensembl chr 2:134,986,817...134,994,365
|
|
G |
PLA2G1B |
phospholipase A2 group IB |
increases activity |
EXP |
Melitten results in increased activity of PLA2G1B protein |
CTD |
PMID:9092818 |
|
NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,520...40,322,315
|
|
G |
SELE |
selectin E |
increases expression |
EXP |
Melitten results in increased expression of SELE mRNA |
CTD |
PMID:10769290 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
|
G |
MYL9 |
myosin light chain 9 |
decreases phosphorylation |
EXP |
ML 7 results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:10942722 |
|
NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] which results in decreased uptake of Calcium |
CTD |
PMID:9506478 |
|
NCBI chr13:136,509,878...136,809,674
Ensembl chr13:136,509,755...136,809,668
|
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:17680988 |
|
NCBI chr15:110,705,548...110,773,037
Ensembl chr15:110,705,496...110,771,728
|
|
G |
IL6 |
interleukin 6 |
decreases expression multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL6 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of IL6 protein] |
CTD |
PMID:24105867 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
increases expression affects localization |
EXP |
Pioglitazone results in increased expression of ABCA1 mRNA Pioglitazone affects the localization of ABCA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions increases secretion |
EXP |
Pioglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol] Pioglitazone results in increased secretion of APOA1 protein |
CTD |
PMID:16530456 |
|
NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,392...44,218,713
|
|
G |
CLDN3 |
claudin 3 |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [deoxynivalenol results in decreased expression of CLDN3 protein] |
CTD |
PMID:36596350 |
|
NCBI chr 3:11,019,073...11,020,102
Ensembl chr 3:11,019,073...11,020,102
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Pioglitazone inhibits the reaction [deoxynivalenol results in decreased expression of CLDN4 protein] |
CTD |
PMID:36596350 |
|
NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925
|
|
G |
LIPG |
lipase G, endothelial type |
decreases expression |
EXP |
Pioglitazone results in decreased expression of LIPG mRNA; Pioglitazone results in decreased expression of LIPG protein |
CTD |
PMID:15953354 |
|
NCBI chr 1:99,081,940...99,110,671
Ensembl chr 1:99,081,938...99,110,874
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Pioglitazone promotes the reaction [Troglitazone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17065204 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Pioglitazone promotes the reaction [Troglitazone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17065204 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases activity |
EXP |
Troglitazone inhibits the reaction [Pioglitazone results in increased activity of PPARG protein] |
CTD |
PMID:17065204 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
increases expression affects localization |
EXP |
Pioglitazone results in increased expression of SCARB1 mRNA Pioglitazone affects the localization of SCARB1 protein |
CTD |
PMID:16530456 |
|
NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,568
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl affects the localization of and results in increased activity of AHR protein] |
CTD |
PMID:12970578 |
|
NCBI chr 9:86,511,866...86,555,950
Ensembl chr 9:86,511,369...86,555,943
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Quercetin inhibits the reaction [[Antimycin A co-treated with Deoxyglucose] results in increased expression of BAX protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
CAV1 |
caveolin 1 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of and results in increased phosphorylation of CAV1 protein] |
CTD |
PMID:19608276 |
|
NCBI chr18:29,648,120...29,682,451
Ensembl chr18:29,649,992...29,682,465
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions decreases activity |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased activity of CYP1A1 protein]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 mRNA]; Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]; Quercetin inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein] Quercetin results in decreased activity of CYP1A1 protein |
CTD |
PMID:12970578 PMID:19608276 |
|
NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [Linoleic Acid results in increased expression of IL6 mRNA] |
CTD |
PMID:15051824 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Quercetin promotes the reaction [[Antimycin A co-treated with Deoxyglucose] results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:25087994 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:21375526 |
|
NCBI chr12:44,174,944...44,219,875
Ensembl chr12:44,174,948...44,218,146
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PECAM1 protein] |
CTD |
PMID:21375526 |
|
NCBI chr12:14,667,643...14,723,296
Ensembl chr12:14,649,044...14,723,293
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
Quercetin inhibits the reaction [Linoleic Acid results in increased activity of PPARG protein] |
CTD |
PMID:15051824 |
|
NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
|
|
G |
SELE |
selectin E |
multiple interactions |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELE mRNA] |
CTD |
PMID:19608276 |
|
NCBI chr 4:81,289,061...81,299,657
|
|
G |
SELP |
selectin P |
multiple interactions |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of SELP mRNA] |
CTD |
PMID:19608276 |
|
NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:19605544 |
|
NCBI chr 1:7,289,278...7,323,418
Ensembl chr 1:7,289,831...7,323,146
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
Quercetin inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of VCAM1 mRNA]; Quercetin inhibits the reaction [Linoleic Acid results in increased expression of VCAM1 mRNA] |
CTD |
PMID:15051824 PMID:19608276 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
CYP2B6B |
cytochrome P450 family 2 subfamily B member 6B |
increases expression |
EXP |
Rifampin results in increased expression of CYP2B6B mRNA |
CTD |
PMID:19464568 |
|
NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,334
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
multiple interactions |
EXP |
Rutin inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:19605544 |
|
NCBI chr 1:7,289,278...7,323,418
Ensembl chr 1:7,289,831...7,323,146
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
SB 203580 affects the reaction [etoxazole affects the phosphorylation of AKT1 protein] |
CTD |
PMID:31744678 |
|
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX mRNA] |
CTD |
PMID:38438008 |
|
NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 mRNA] |
CTD |
PMID:38438008 |
|
NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:38438008 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CCL2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA] |
CTD |
PMID:19265715 PMID:23380242 |
|
NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of CLDN1 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA] |
CTD |
PMID:37271275 PMID:38438008 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 mRNA] |
CTD |
PMID:38438008 |
|
NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of LDHA protein] |
CTD |
PMID:38438008 |
|
NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
|
|
G |
LOC110258578 |
interleukin-1 beta-like |
multiple interactions |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein] |
CTD |
PMID:37271275 PMID:38438008 |
|
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [etoxazole results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:31744678 |
|
NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA] |
CTD |
PMID:37271275 |
|
NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [etoxazole results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:31744678 |
|
NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[SB 203580 co-treated with etoxazole] results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:31744678 |
|
NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA] |
CTD |
PMID:37271275 |
|
NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
|
|
G |
OCLN |
occludin |
multiple interactions |
EXP |
[SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of OCLN protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA] |
CTD |
PMID:37271275 PMID:38438008 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions |
EXP |
SB 203580 affects the reaction [etoxazole affects the phosphorylation of RPS6 protein] |
CTD |
PMID:31744678 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
SB 203580 affects the reaction [etoxazole affects the phosphorylation of RPS6KB1 protein] |
CTD |
PMID:31744678 |
|
NCBI chr12:36,111,584...36,159,287
Ensembl chr12:36,111,653...36,160,376
|
|
G |
STAT1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:21783819 |
|
NCBI chr15:95,593,201...95,646,324
Ensembl chr15:95,593,211...95,646,260
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:21783819 |
|
NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of TJP1 protein] |
CTD |
PMID:38438008 |
|
NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of TNF protein] |
CTD |
PMID:38438008 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] |
CTD |
PMID:23380242 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of ATF6 protein] |
CTD |
PMID:37659622 |
|
NCBI chr 4:88,591,279...88,806,156
Ensembl chr 4:88,591,288...88,805,304
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2L1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr17:35,366,139...35,415,798
Ensembl chr17:35,366,143...35,414,694
|
|
G |
BECN1 |
beclin 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased cleavage of CASP3 protein] |
CTD |
PMID:37659622 |
|
NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
|
|
G |
CLDN1 |
claudin 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of CLDN1 protein] |
CTD |
PMID:36754226 |
|
NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in decreased expression of CLDN4 protein] |
CTD |
PMID:37659622 |
|
NCBI chr 3:11,039,711...11,053,930
Ensembl chr 3:11,039,706...11,053,925
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of CYCS protein] |
CTD |
PMID:37659622 |
|
NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
|
|
G |
DCTN4 |
dynactin subunit 4 |
multiple interactions |
EXP |
Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr 2:151,681,001...151,713,923
Ensembl chr 2:151,681,003...151,783,746
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of DDIT3 protein] |
CTD |
PMID:37659622 |
|
NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:37659622 |
|
NCBI chr12:14,881,913...14,963,290
Ensembl chr12:14,881,923...14,963,284
|
|
G |
FGD4 |
FYVE, RhoGEF and PH domain containing 4 |
multiple interactions |
EXP |
Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028
|
|
G |
FIS1 |
fission, mitochondrial 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat affects the expression of FIS1 protein]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr 3:8,938,250...8,942,102
Ensembl chr 3:8,937,453...8,946,955
|
|
G |
FOXO1 |
forkhead box O1 |
increases expression affects localization |
EXP |
Sirolimus results in increased expression of FOXO1 mRNA; Sirolimus results in increased expression of FOXO1 protein Sirolimus affects the localization of FOXO1 protein |
CTD |
PMID:20622751 |
|
NCBI chr11:15,317,222...15,410,059
Ensembl chr11:15,317,124...15,410,473
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
|
|
G |
H2AX |
H2A.X variant histone |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of H2AX protein] |
CTD |
PMID:37659622 |
|
NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in decreased expression of HSPA5 protein] |
CTD |
PMID:37659622 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
G |
IGF2 |
insulin like growth factor 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of IGF2 mRNA; Sirolimus results in decreased expression of IGF2 protein |
CTD |
PMID:20622751 |
|
NCBI chr 2:1,469,183...1,496,417
|
|
G |
INS |
insulin |
multiple interactions decreases expression |
EXP |
Sirolimus inhibits the reaction [Glucose results in increased secretion of INS protein] Sirolimus results in decreased expression of INS mRNA; Sirolimus results in decreased expression of INS protein |
CTD |
PMID:20622751 |
|
NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
|
|
G |
LAMP2 |
lysosomal associated membrane protein 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased expression of LAMP2 protein] |
CTD |
PMID:36754226 |
|
NCBI chr X:98,586,718...98,623,939
Ensembl chr X:98,556,710...98,623,940
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; Sirolimus inhibits the reaction [Benzo(a)pyrene results in decreased lipidation of MAP1LC3B protein] |
CTD |
PMID:34811946 PMID:36754226 |
|
NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in increased phosphorylation of MTOR protein] |
CTD |
PMID:37659622 |
|
NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
|
|
G |
MYD88 |
MYD88 innate immune signal transduction adaptor |
multiple interactions |
EXP |
Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]; Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]; Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat affects the expression of FIS1 protein]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat affects the expression of OPA1 protein]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]; Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]] |
CTD |
PMID:34811946 |
|
NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
|
|
G |
NEUROD1 |
neuronal differentiation 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of NEUROD1 mRNA |
CTD |
PMID:20622751 |
|
NCBI chr15:87,175,629...87,179,953
Ensembl chr15:87,175,765...87,179,959
|
|
G |
OCLN |
occludin |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in decreased expression of OCLN protein] |
CTD |
PMID:37659622 |
|
NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
|
|
G |
OPA1 |
OPA1 mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat affects the expression of OPA1 protein]]; Sirolimus affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]] |
CTD |
PMID:34811946 |
|
NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083
|
|
G |
PDX1 |
pancreatic and duodenal homeobox 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of PDX1 mRNA |
CTD |
PMID:20622751 |
|
NCBI chr11:5,303,609...5,309,063
Ensembl chr11:5,303,609...5,309,063
|
|
G |
SELP |
selectin P |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Zymosan analog results in increased expression of SELP protein] |
CTD |
PMID:16797888 |
|
NCBI chr 4:81,376,804...81,401,240
Ensembl chr 4:81,365,740...81,399,955
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA] |
CTD |
PMID:34811946 |
|
NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]] |
CTD |
PMID:34811946 |
|
NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
|
|
G |
TJP2 |
tight junction protein 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [3-acetyldeoxynivalenol results in decreased expression of TJP2 protein] |
CTD |
PMID:37659622 |
|
NCBI chr 1:222,474,518...222,612,989
Ensembl chr 1:222,474,639...222,612,983
|
|
G |
VCAM1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Zymosan analog results in increased expression of VCAM1 protein] |
CTD |
PMID:16797888 |
|
NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
|
|
|
G |
GJA1 |
gap junction protein alpha 1 |
decreases expression |
EXP |
Sunitinib results in decreased expression of GJA1 protein |
CTD |
PMID:32877659 |
|
NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
|
|
G |
TNNT2 |
troponin T2, cardiac type |
decreases expression |
EXP |
Sunitinib results in decreased expression of TNNT2 protein |
CTD |
PMID:32877659 |
|
NCBI chr10:23,749,528...23,759,696
Ensembl chr10:23,749,335...23,763,396
|
|
|
G |
ESR1 |
estrogen receptor 1 |
affects binding |
EXP |
Tamoxifen metabolite binds to ESR1 protein |
CTD |
PMID:16790557 |
|
NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
|
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression |
EXP |
Tunicamycin results in increased expression of HSP90B1 protein |
CTD |
PMID:15049342 PMID:17416481 |
|
NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
decreases response to substance increases expression |
EXP |
HSPA5 results in decreased susceptibility to Tunicamycin Tunicamycin results in increased expression of HSPA5 protein |
CTD |
PMID:15049342 PMID:16920763 PMID:17416481 PMID:17464326 PMID:18086661 |
|
NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
|
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16239170 |
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [sodium arsenite results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:16239170 |
|
NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
|
|
G |
RPS6 |
ribosomal protein S6 |
decreases phosphorylation multiple interactions |
EXP |
Wortmannin results in decreased phosphorylation of RPS6 protein Wortmannin promotes the reaction [Ivermectin results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:31400776 |
|
NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
EXP |
Wortmannin inhibits the reaction [TNF protein results in increased expression of HIF1A protein] |
CTD |
PMID:11514583 |
|
NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
|
|